Jakob Loven, Ph.D.
Jakob Loven, Ph.D., is a partner at Nextech Invest Ltd. An accomplished oncology-focused entrepreneur and life science venture capitalist, Jakob brings to Nextech his extensive experience in creating, launching and building early stage therapeutic-based platform biotechnology companies, including Relay Therapeutics and Syros Pharmaceuticals (NASDAQ: SYRS).
Today, Jakob serves as a board member of A2 Biotherapeutics, Vividion, Arrakis, Kronos (NASDAQ:KRON) and IconOVir. He is a former board member of Arvinas (NASDAQ: ARVN), and board observer of Kinnate (NASDAQ:KNTE), Turning Point Therapeutics (NASDAQ: TPTX) and Autolus (NASDAQ: AUTL).
Jakob earned his Ph.D. in medical sciences focused on oncology from Karolinska Institutet and earned his B.A. in biomedical sciences in the UK.
Born in South America, raised in Asia, and educated in Europe and the U.S., Jakob is citizen of everywhere and as such feels at home wherever he travels, bringing with him a natural disposition towards new experiences, people, and cultures.